Wockhardt Ltd (WOCKPHARMA)
₹1,901.10
Mkt cap
₹30,895 Cr
P/E ratio
77.50
P/B
6.25
Div yield
0.00%
ROE
6.11%
ROCE
7.55%
EPS (TTM)
₹24.53
Book value
₹304
52W range
1,087–2,422
Sector
Healthcare
Price history
Previous close
Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments). [1]
NSE WOCKPHARMABSE 532300
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthLow
TechnicalsNeutral
52-week range
−21.52% from high₹1,901
₹1,087+74.94% from low₹2,422
Current
₹1,901.10
Prev close
₹1,922.90
Day
−1.13%
Price performance
1D
−2.15%
1W
+4.43%
1M
−14.25%
3M
−1.18%
6M
+35.20%
1Y
+38.48%
YTD
+35.19%
Financials
Revenue, profit & margin
P/E ratio
77.5×
WOCKPHARMA is 128% above the sector median of 34.0×
WOCKPHARMA77.5×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 644 | 753 | 701 | 700 | 739 | 809 | 721 | 743 | 738 | 782 | 888 | 965 | 929 | |
| Expenses | 628 | 681 | 664 | 759 | 648 | 699 | 593 | 679 | 666 | 604 | 711 | 740 | 737 | |
| Operating Profit | 16 | 72 | 37 | -59 | 91 | 110 | 128 | 64 | 72 | 178 | 177 | 225 | 192 | |
| OPM % | 2.5% | 10% | 5% | -8% | 12% | 14% | 18% | 9% | 10% | 23% | 20% | 23% | 21% | |
| Other Income | 0 | 24 | 8 | 10 | 30 | 9 | 8 | 15 | -77 | 21 | 15 | 67 | 31 | |
| Interest | 79 | 76 | 77 | 73 | 73 | 73 | 60 | 48 | 48 | 55 | 60 | 50 | 52 | |
| Depreciation | 55 | 55 | 55 | 58 | 54 | 55 | 55 | 53 | 56 | 53 | 65 | 53 | 55 | |
| Profit before tax | -118 | -35 | -87 | -180 | -6 | -9 | 21 | -22 | -109 | 91 | 67 | 189 | 116 | |
| Tax % | 15% | 109% | -1% | -2% | 167% | 78% | 5% | 105% | -1% | 10% | 9% | 13% | 8% | |
| Net Profit | -136 | -73 | -86 | -177 | -16 | -16 | 20 | -45 | -108 | 82 | 61 | 164 | 107 | |
| EPS in Rs | -9.30 | -5.34 | -5.76 | -11.02 | -0.91 | -1.43 | 0.86 | -1.54 | -5.54 | 4.80 | 3.63 | 10.22 | 6.52 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
2 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.45% · closed higher next day 24 of last 59
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 14 Nov '23◦ | 14 Feb '24◦ | 28 May '24◦ | 9 Aug '24◦ | 13 Nov '24◦ | 7 Feb '25 | 29 May '25◦ | 8 Aug '25 | 3 Nov '25 | 10 Feb '26 | 4 May '26◦ | 10 Aug '26◦ |
| Earnings day | −1.47% | −0.96% | +0.56% | +3.03% | −1.62% | −3.13% | +8.80% | −3.25% | +10.32% | +1.27% | +7.86% | −1.13% |
| +1 day | +12.51% | +8.62% | −4.46% | −2.10% | −4.48% | −7.98% | +8.85% | −3.86% | +6.54% | −0.64% | +20.48% | −4.34% |
| +5 days | +16.54% | +26.44% | −7.06% | +2.81% | +8.88% | −16.11% | +11.78% | −0.94% | +3.93% | −1.06% | +10.20% | −3.69% |
| +15 days | +19.96% | +23.53% | +2.34% | +10.24% | +17.35% | −27.32% | +28.51% | −7.01% | −0.88% | −8.57% | +19.31% | −4.17% |
| +30 days | +48.89% | +33.41% | +58.37% | +4.76% | +19.12% | −13.60% | +30.46% | −2.94% | +5.91% | −15.16% | +41.95% | +20.63% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202649.33%Promoter
Promoters49.33%0.24
FIIs7.02%0.21
DIIs9.00%0.24
Public34.64%0.20
Government0.01%0.01
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Wockhardt | ₹1,901.10 | 77.49 | 30,895 | 0.00% | 107 | +973.63% | 929 | +25.88% | 7.55% |
| Median: 158 Co. | ₹426.38 | 34.03 | 1,921 | 0.08% | 14 | +24.68% | 175 | +19.54% | 15.12% |
Filings
Annual reports15
Concall transcripts11
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 27 Oct - Share Allotment Committee of Board of the Company has allotted 20000 equity shares of face value of Rs 5 each on 27th October, 2026 pursuant …Board Meeting Intimation for Intimation Of The Meeting Of Board Of Wockhardt Limited ('The Company') 27 Oct - Board meets on 2 November 2026 to approve Q2 FY27 and half-year unaudited results; trading window remains closed.Announcement under Regulation 30 (LODR)-Newspaper Publication 24 Oct - Pursuant to Regulation 30 read with Schedule III Part A Para A of the SEBI (LODR) Regulations, 2015, we enclose herewith a copy of newspaper …Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9 Oct - Regulation 74(5) certificate received for quarter ended 30 September 2026.Closure of Trading Window 25 Sep - Trading window closed1 Oct 2026 until 48 hours after Q2 FY26 results.